International Journal of Radiation Oncology * Biology * Physics
Volume 71, Issue 5 , Pages 1295-1301 , 1 August 2008

In Patients Experiencing Biochemical Failure After Radiotherapy, Pretreatment Risk Group and PSA Velocity Predict Differences in Overall Survival and Biochemical Failure-Free Interval

  • Daniel E. Soto, M.D., M.S.

      Affiliations

    • Department of Radiation Oncology, University of Michigan, Ann Arbor, MI
    • Corresponding Author InformationReprint requests to: Daniel E. Soto, M.D., M.S., Department of Radiation Oncology, University of Michigan, 1500 E. Medical Center Dr., B2 C490, Box 0010, Ann Arbor, MI 48109-0010. Tel: (734) 936-4288; Fax (734) 763-7370
    • ,
  • Rebecca R. Andridge, M.S.

      Affiliations

    • Department of Biostatistics, University of Michigan, Ann Arbor, MI
    • ,
  • Charlie C. Pan, M.D.

      Affiliations

    • Department of Radiation Oncology, University of Michigan, Ann Arbor, MI
    • ,
  • Scott G. Williams, F.R.A.N.Z.C.R.

      Affiliations

    • Division of Radiation Oncology, Peter MacCallum Cancer Centre and University of Melbourne, Melbourne, VC, Australia
    • ,
  • Jeremy M.G. Taylor, Ph.D.

      Affiliations

    • Department of Biostatistics, University of Michigan, Ann Arbor, MI
    • ,
  • Howard M. Sandler, M.D., M.S.

      Affiliations

    • Department of Radiation Oncology, University of Michigan, Ann Arbor, MI

Received 12 January 2008 ,Revised 27 February 2008 ,Accepted 29 February 2008.

References 

  1. D'Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998;280:969–974
  2. Zelefsky MJ, Leibel SA, Gaudin PB, et al. Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer. Int J Radiat Oncol Biol Phys. 1998;41:491–500
  3. Roach M, Weinberg V, McLaughlin PW, et al. Serum prostate-specific antigen and survival after external beam radiotherapy for carcinoma of the prostate. Urology. 2003;61:730–735
  4. Pisansky TM, Kahn MJ, Rasp GM, et al. A multiple prognostic index predictive of disease outcome after irradiation for clinically localized prostate carcinoma. Cancer. 1997;79:337–344
  5. Shipley WU, Thames HD, Sandler HM, et al. Radiation therapy for clinically localized prostate cancer: A multi-institutional pooled analysis. JAMA. 1999;281:1598–1604
  6. Pisansky TM, Kahn MJ, Bostwick DG. An enhanced prognostic system for clinically localized carcinoma of the prostate. Cancer. 1997;79:2154–2161
  7. Kattan MW, Zelefsky MJ, Kupelian PA, et al. Pretreatment nomogram for predicting the outcome of three-dimensional conformal radiotherapy in prostate cancer. J Clin Oncol. 2000;18:3352–3359
  8. Makarov DV, Trock BJ, Humphreys EB, et al. Updated nomogram to predict pathologic stage of prostate cancer given prostate-specific antigen level, clinical stage, and biopsy Gleason score (Partin tables) based on cases from 2000 to 2005. Urology. 2007;69:1095–1101
  9. Fukunaga-Johnson N, Sandler HM, McLaughlin PW, et al. Results of 3D conformal radiotherapy in the treatment of localized prostate cancer. Int J Radiat Oncol Biol Phys. 1997;38:311–317
  10. Zagars GK, Pollack A, von Eschenbach AC. Prognostic factors for clinically localized prostate carcinoma: Analysis of 938 patients irradiated in the prostate specific antigen era. Cancer. 1997;79:1370–1380
  11. Movsas B, Hanlon AL, Teshima T, et al. Analyzing predictive models following definitive radiotherapy for prostate carcinoma. Cancer. 1997;80:1093–1102
  12. Kupelian PA, Potters L, Khuntia D, et al. Radical prostatectomy, external beam radiotherapy <72 Gy, external beam radiotherapy > or =72 Gy, permanent seed implantation, or combined seeds/external beam radiotherapy for stage T1-T2 prostate cancer. Int J Radiat Oncol Biol Phys. 2004;58:25–33
  13. Zietman AL, DeSilvio ML, Slater JD, et al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: A randomized controlled trial. JAMA. 2005;294:1233–1239
  14. D'Amico AV, Schultz D, Loffredo M, et al. Biochemical outcome following external beam radiation therapy with or without androgen suppression therapy for clinically localized prostate cancer. JAMA. 2000;284:1280–1283
  15. Crook J, Ludgate C, Malone S, et al. Report of a multicenter Canadian phase III randomized trial of 3 months vs. 8 months neoadjuvant androgen deprivation before standard-dose radiotherapy for clinically localized prostate cancer. Int J Radiat Oncol Biol Phys. 2004;60:15–23
  16. Sengupta S, Myers RP, Slezak JM, et al. Preoperative prostate specific antigen doubling time and velocity are strong and independent predictors of outcomes following radical prostatectomy. J Urol. 2005;174:2191–2196
  17. D'Amico AV, Renshaw AA, Sussman B, et al. Pretreatment PSA velocity and risk of death from prostate cancer following external beam radiation therapy. JAMA. 2005;294:440–447
  18. D'Amico AV, Moul J, Carroll PR, et al. Prostate specific antigen doubling time as a surrogate end point for prostate cancer specific mortality following radical prostatectomy or radiation therapy. J Urol. 2004;172(5 Pt 2):S42–S47
  19. D'Amico AV, Chen MH, Roehl KA, et al. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med. 2004;351:125–135
  20. Sengupta S, Blute ML, Bagniewski SM, et al. Increasing prostate specific antigen following radical prostatectomy and adjuvant hormonal therapy: Doubling time predicts survival. J Urol. 2006;175:1684–1690
  21. Zagars GK, Pollack A. Kinetics of serum prostate-specific antigen after external beam radiation for clinically localized prostate cancer. Radiother Oncol. 1997;44:213–221
  22. Patel DA, Presti JC, McNeal JE, et al. Preoperative PSA velocity is an independent prognostic factor for relapse after radical prostatectomy. J Clin Oncol. 2005;23:6157–6162
  23. Petit JH, Chen MH, Loffredo M, et al. Prostate-specific antigen recurrence and mortality after conventional dose radiation therapy in select men with low-risk prostate cancer. Cancer. 2006;107:2180–2185
  24. Roach M, Hanks G, Thames H, et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys. 2006;65:965–974
  25. Pollack A, Hanlon AL, Movsas B, et al. Biochemical failure as a determinant of distant metastasis and death in prostate cancer treated with radiotherapy. Int J Radiat Oncol Biol Phys. 2003;57:19–23
  26. Kupelian PA, Buchsbaum JC, Patel C, et al. Impact of biochemical failure on overall survival after radiation therapy for localized prostate cancer in the PSA era. Int J Radiat Oncol Biol Phys. 2002;52:704–711
  27. Kwan W, Pickles T. In regard to Kupelian, et al.: Impact of biochemical failure on overall survival after radiation therapy for localized prostate cancer in the PSA era. IJROBP 2002;52:704–711. Int J Radiat Oncol Biol Phys. 2002;54:1577–1579author reply 1579
  28. Sandler HM, Dunn RL, McLaughlin PW, et al. Overall survival after prostate-specific-antigen-detected recurrence following conformal radiation therapy. Int J Radiat Oncol Biol Phys. 2000;48:629–633
  29. Williams SG, Duchesne GM, Millar JL, et al. Both pretreatment prostate-specific antigen level and posttreatment biochemical failure are independent predictors of overall survival after radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2004;60:1082–1087
  30. Kwan W, Pickles T, Duncan G, et al. PSA failure and the risk of death in prostate cancer patients treated with radiotherapy. Int J Radiat Oncol Biol Phys. 2004;60:1040–1046
  31. Dotan ZA, Bianco FJ, Rabbani F, et al. Pattern of prostate-specific antigen (PSA) failure dictates the probability of a positive bone scan in patients with an increasing PSA after radical prostatectomy. J Clin Oncol. 2005;23:1962–1968
  32. Eggener SE, Roehl KA, Yossepowitch O, et al. Prediagnosis prostate specific antigen velocity is associated with risk of prostate cancer progression following brachytherapy and external beam radiation therapy. J Urol. 2006;176(4 Pt 1):1399–1403
  33. Palma D, Tyldesley S, Blood P, et al. Pretreatment PSA velocity as a predictor of disease outcome following radical radiation therapy. Int J Radiat Oncol Biol Phys. 2007;67:1425–1429
  34. Lee AK, D'Amico AV. Utility of prostate-specific antigen kinetics in addition to clinical factors in the selection of patients for salvage local therapy. J Clin Oncol. 2005;23:8192–8197
  35. D'Amico AV, Loffredo M, Renshaw AA, et al. Six-month androgen suppression plus radiation therapy compared with radiation therapy alone for men with prostate cancer and a rapidly increasing pretreatment prostate-specific antigen level. J Clin Oncol. 2006;24:4190–4195
  36. Williams SG, Taylor JM, Liu N, et al. Use of individual fraction size data from 3756 patients to directly determine the alpha/beta ratio of prostate cancer. Int J Radiat Oncol Biol Phys. 2007;68:24–33
  37. Coogan CL, Latchamsetty KC, Greenfield J, et al. Increasing the number of biopsy cores improves the concordance of biopsy Gleason score to prostatectomy Gleason score. BJU Int. 2005;96:324–327
  38. Lee IH, Roberts R, Shah RB, et al. Perineural invasion is a marker for pathologically advanced disease in localized prostate cancer. Int J Radiat Oncol Biol Phys. 2007;68:1059–1064
  39. Spalding AC, Daignault S, Sandler HM, et al. Percent positive biopsy cores as a prognostic factor for prostate cancer treated with external beam radiation. Urology. 2007;69:936–940
  40. Beard CJ, Chen MH, Cote K, et al. Perineural invasion is associated with increased relapse after external beam radiotherapy for men with low-risk prostate cancer and may be a marker for occult, high-grade cancer. Int J Radiat Oncol Biol Phys. 2004;58:19–24
  41. Beard C, Schultz D, Loffredo M, et al. Perineural invasion associated with increased cancer-specific mortality after external beam radiation therapy for men with low- and intermediate-risk prostate cancer. Int J Radiat Oncol Biol Phys. 2006;66:403–407
  42. D'Amico AV, Schultz D, Silver B, et al. The clinical utility of the percent of positive prostate biopsies in predicting biochemical outcome following external-beam radiation therapy for patients with clinically localized prostate cancer. Int J Radiat Oncol Biol Phys. 2001;49:679–684
  43. D'Amico AV, Renshaw AA, Cote K, et al. Impact of the percentage of positive prostate cores on prostate cancer-specific mortality for patients with low or favorable intermediate-risk disease. J Clin Oncol. 2004;22:3726–3732
  44. Nguyen PL, Chen MH, Renshaw AA, et al. Effect of definition of preradiotherapy prostate-specific antigen velocity on its association with prostate cancer-specific mortality and all-cause mortality. Urology. 2007;70:288–293
  45. Bates AT, Pickles T, Paltiel C. PSA doubling time kinetics during prostate cancer biochemical relapse after external beam radiation therapy. Int J Radiat Oncol Biol Phys. 2005;62:148–153
  46. Buyyounouski MK, Hanlon AL, Horwitz EM, et al. Biochemical failure and the temporal kinetics of prostate-specific antigen after radiation therapy with androgen deprivation. Int J Radiat Oncol Biol Phys. 2005;61:1291–1298

 Note—An online CME test for this article can be taken at http://asro.astro.org under Continuing Education.

 Conflict of interest: none.

PII: S0360-3016(08)00503-8

doi: 10.1016/j.ijrobp.2008.02.069

International Journal of Radiation Oncology * Biology * Physics
Volume 71, Issue 5 , Pages 1295-1301 , 1 August 2008

Article Tools

* Image Usage & Resolution